[Explanation] Not long ago, the nasal spray influenza virus vector new crown vaccine jointly developed by Xiamen University, the University of Hong Kong, and Beijing Wantai Biosciences launched clinical trials, which also marked that the new crown pneumonia vaccines developed by China's five technical routes have entered clinical trials. Experimental phase.
Recently, a reporter from China News Service went to Beijing Wantai Biopharmaceutical Co., Ltd. to learn about the research and development of this vaccine.
[Explanation] The nasal spray influenza virus vector new coronavirus vaccine is to insert new coronavirus gene fragments into the influenza virus vector to make a live virus vector vaccine, thereby stimulating the human body to produce an immune response to the new coronavirus.
Qiu Zixin, general manager of the company, introduced that the vaccine developed by this technical route can theoretically provide a certain degree of protection against specific types of influenza.
[Concurrent] Qiu Zixin, General Manager of Beijing Wantai Biopharmaceutical Co., Ltd.
Theoretically speaking, influenza can also be prevented, but because influenza varies greatly, each year the influenza has to be replaced with different strains according to different epidemics.
If this type of influenza (viral vector used in vaccines) is prevalent this year, it can be prevented.
[Explanation] Qiu Zixin said that the technical route of influenza virus vector vaccine is innovative. It mainly protects the human body by inducing cellular immunity.
[Concurrent] Qiu Zixin, General Manager of Beijing Wantai Biopharmaceutical Co., Ltd.
The first viral infection enters the lungs through the nasal cavity. In the nasal cavity we have mucosal cells, which stimulate the mucosal cells to produce cellular immunity.
The human immune system has two main channels to function, one is B cells and the other is T cells.
B cell immunity is the production of antibodies, and T cell immunity is also a way of immunity.
[Explanation] This influenza virus vector new crown vaccine will be vaccinated in the form of a nasal spray. Qiu Zixin believes that this form is not only convenient and fast, but also has its own advantages in resisting viral infections.
[Concurrent] Qiu Zixin, General Manager of Beijing Wantai Biopharmaceutical Co., Ltd.
One of them is that the immune barrier mimics the way of viral infection, which is an advantage. In addition, because it is a live virus, a live virus can continuously stimulate and stimulate more people to produce immune memory and immune response, making it really virus. When infected, it can immediately resist infection and disease.
[Commentary] Qiu Zixin told reporters that they plan to build production workshops specifically for the new crown vaccine and strive to increase vaccine production capacity.
[Concurrent] Qiu Zixin, General Manager of Beijing Wantai Biopharmaceutical Co., Ltd.
If the new crown (vaccine) is to be implemented, a relatively high production capacity is required. We expect to build a new workshop layout according to the (annual) production capacity plan of hundreds of millions of doses.
Reporter Wen Mengxin reports from Beijing
Editor in charge: 【Luo Pan】